Antibodies for guanylyl cyclase receptors
Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.
1. An isolated antibody or antigen-binding portion thereof that selectively binds to an epitope located in an extracellular domain of natriuretic peptide receptor A (NPRA) wherein said epitope forms when said NPRA is bound to atrial natriuretic peptide (ANP), or brain natriuretic peptide (BNP), wherein said antibody or antigen-binding portion thereof is not reactive with the atrial natriuretic peptide (ANP), or brain natriuretic peptide (BNP) binding site of NPRA, wherein said epitope is located in the three dimensional structure of NPRA when NPRA is bound to ANP or BNP, wherein said epitope comprises amino acids within NLTVAVVLPLANTSYPWSWARV (SEQ ID NO:30), VKDEYALTT (SEQ ID NO:31), TMEDGLVN (SEQ ID NO:32), HDGLLLY (SEQ ID NO:33) and VTDGE (SEQ ID NO:34).
2. The antibody or antigen-binding portion thereof according to claim 1 , wherein said antibody or portion thereof binds to the same epitope as an antibody comprising a VH and VL chain, each VH and VL chain comprising hypervariable regions CDR1, CDR2 and CDR3 separated by framework amino acid sequences, the hypervariable regions having amino acid sequences in each VH and VL, wherein
VHCDR1 of said antibody has a sequence of SEQ ID NO:3;
VHCDR2 of said antibody has a sequence selected from the group consisting of SEQ ID NO:4 and 10,
VHCDR3 of said antibody has a sequence of SEQ ID NO:13,
VLCDR1 of said antibody has a sequence of SEQ ID NO:14,
VLCDR2 of said antibody has a sequence of SEQ ID NO:15; and
VLCDR3 of said antibody has a sequence selected from the group consisting of SEQ ID NO: 16, 17 and 18.
3. The antibody or antigen-binding portion thereof according to claim 2 , wherein the antibody or portion thereof comprises a VH and VL chain, each VH and VL chain comprising hypervariable regions CDR1, CDR2 and CDR3 separated by framework amino acid sequences, the hypervariable regions having amino acid sequences selected from one of the following:
5064:
VHCDR1
VHCDR2
VHCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
3)
4)
13)
VLCDR1
VLCDR2
VLCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
14)
15)
16)
5502:
VHCDR1
VHCDR2
VHCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
3)
4)
13)
VLCDR1
VLCDR2
VLCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
14)
15)
17)
5504:
VHCDR1
VHCDR2
VHCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
3)
4)
13)
VLCDR1
VLCDR2
VLCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
14)
15)
18)
5591:
VHCDR1
VHCDR2
VHCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
3)
10)
13)
VLCDR1
VLCDR2
VLCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
14)
15)
17), and
5592
VHCDR1
VHCDR2
VHCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
3)
10)
13)
VLCDR1
VLCDR2
VLCDR3
(SEQ ID NO:
(SEQ ID NO:
(SEQ ID NO:
14)
15)
18).